Outcomes of Kidney Transplantation in Patients with Prosthetic Heart Valves
H. Ouahmi
Nephrology, Dialysis, Transplantation, Nice University Hospital, Nice, France
Meeting: 2021 American Transplant Congress
Abstract number: 72
Keywords: Kidney transplantation, Mortality, N/A, Valve replacement
Topic: Clinical Science » Kidney » Kidney: Cardiovascular and Metabolic Complications
Session Information
Session Name: Kidney: Cardiovascular and Metabolic Complications
Session Type: Rapid Fire Oral Abstract
Date: Saturday, June 5, 2021
Session Time: 6:00pm-7:00pm
Presentation Time: 6:25pm-6:30pm
Location: Virtual
*Purpose: Due to the aging of the population, a growing number of patients with end-stage kidney disease (ESKD) require cardiac valve replacement. As a consequence, the number of kidney transplant candidates with prosthetic heart valves (PHVs) is increasing. Yet, outcomes of kidney transplantation in these patients are unknown. We provide the first report of post-transplant outcomes in patients with prosthetic heart valves at time of kidney transplantation.
*Methods: We conducted a matched cohort study among kidney transplant recipients from the French multicentric and prospective DIVAT cohort. We compared post-transplant outcomes in patients with left-sided PHVs at time of kidney transplantation (2000-2019) and a population of recipients without PHV matched for re-transplant dialysis time, recurrent renal disease, diabetes, cardiovascular events and pre-transplant donor-specific antibodies. Cox proportional hazards regression was used to identify independent predictors of death.
*Results: Of 23018 kidney transplant recipients in the database, 368 were included in the study, 92 (0.4%) of whom had a PHV at time of transplantation and 276 had not. Delayed graft function and post-operative bleeding occurred more frequently in patients with PHVs than in those without PHV (34.8% vs 14.1%, p<0.0001 and 47.8% vs 11.6 %, p<0.0001, respectively). Kidney graft survival was similar between groups. 5-year overall survival was 68.5 % in patients with PHV versus 87.9 % in patients without PHV (HR, 2.72 [1.57-4.70], p=0.0004 by log-rank). Deaths from infection, endocarditis and bleeding were significantly more frequent in patients with PHV (14.1% vs 4.7%, p=0.004; 3.2% vs 0.4%, p=0.049; 3.3% vs 0%, p=0.02; respectively). In contrast with a bioprosthetic valve, a mechanical valve at time of transplantation was an independent risk factor for mortality (HR, 2.89 [1.68-4.97], p=0.0001) together with recipient age, pre-transplant dialysis time, diabetes and cardiac events.
*Conclusions: ESKD patients with prosthetic heart valves have high mortality rates after kidney transplantation (more than 30% at 5 years post-transplantation). These data suggest that mechanical valves, but not biological valves, increase risks of post-transplant mortality, which has to be considered when choosing the type of prosthetic heart valve in ESKD patients eligible for kidney transplantation.
To cite this abstract in AMA style:
Ouahmi H. Outcomes of Kidney Transplantation in Patients with Prosthetic Heart Valves [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-kidney-transplantation-in-patients-with-prosthetic-heart-valves/. Accessed November 22, 2024.« Back to 2021 American Transplant Congress